Related Experiment Video
Updated: Aug 12, 2026
Microvascular Decompression: Salient Surgical Principles and Technical Nuances
Published on: July 5, 2011
[Experience with maxipime in neurosurgical clinic]
1A. L. Polenov Russian Neurosurgical Institute, St. Petersburg.
Abstract:
Cefepime (Maxipime, Bristol-Myers Squibb), a 4th generation cephalosporin was used in the postoperative treatment of 121 patients of Anesthesiology and Intensive Care Unit of Neurosurgical Clinics. The patients were divided into groups by the risk factor of pyoseptic complications. The results were estimated by the number and nature of the complications such as increasing liquor neutrophilic cytosis, systemic inflammations and others. The findings (increasing liquor neutrophilic cytosis only in 2 patients and endobronchitis in 4 patients) and good tolerance of cefepime (Maxipime) were in favour of its use in a dose of 1 g administered intravenously dropwise during initial narcosis and in 12 hours as an efficient agent for perioperative prophylaxis in neurosurgical patients.
Insights
Cefepime effectively prevented postoperative infections in 121 neurosurgery patients, showing good tolerance. This fourth-generation cephalosporin proved efficient for perioperative prophylaxis, with minimal complications observed.
Area of Science:
- Infectious Diseases
- Neurosurgery
- Pharmacology
Background:
- Postoperative infections pose significant risks in neurosurgery.
- Effective perioperative prophylaxis is crucial for patient outcomes.
Purpose of the Study:
- To evaluate the efficacy and safety of cefepime for perioperative prophylaxis in neurosurgical patients.
- To assess the rate of pyoseptic complications and tolerance of cefepime.
Main Methods:
- A study involving 121 neurosurgical patients receiving cefepime (Maxipime) postoperatively.
- Patients were grouped based on pyoseptic complication risk factors.
- Complications like neutrophilic cytosis and systemic inflammation were monitored.
Main Results:
- Cefepime demonstrated good tolerance in patients.
- Only 2 patients experienced increased liquor neutrophilic cytosis.
- Endobronchitis was observed in 4 patients, indicating a low complication rate.
Conclusions:
- Cefepime is an efficient agent for perioperative prophylaxis in neurosurgical patients.
- A dosage of 1g administered intravenously is recommended.
- Cefepime offers a favorable safety profile with minimal adverse events.
